Type 1 Diabetes Mellitus: Epidemiology, Genetics, Pathogenesis And Clinical Manifestations

  • Marian Rewers

Abstract

Type 1 diabetes is caused by pancreatic β-cell destruction that leads to loss of insulin secretion and absolute insulin deficiency. Type 1 diabetes accounts for about 10% of all diabetes, affecting approximately 1.4 million people in the U.S., and 10–20 million globally.1 Diabetes is one of the most common severe chronic diseases of childhood affecting 1 in 300 children and as many as 1 in 100 adults during the life span.2

Keywords

Glutamic Acid Decarboxylase United Kingdom Prospective Diabetes Study Islet Cell Antibody Congenital Rubella Syndrome Islet Autoimmunity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rewers M. The changing face of the epidemiology of insulin-dependent diabetes mellitus (IDDM): Research designs and models of disease causation. Ann Med 23: 419–426, 1991.PubMedCrossRefGoogle Scholar
  2. 2.
    Rewers M, LaPorte RE, King H, Tuomilehto J. Trends in the prevalence and incidence of diabetes: insulin-dependent diabetes mellitus in childhood. World Health Stat Q 41: 179–189, 1988.PubMedGoogle Scholar
  3. 3.
    American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20: 1183–1197, 1997.Google Scholar
  4. 4.
    Atkinson MAEisenbarth GS. Type 1 Diabetes: New Perspectives on Disease Pathogenesis and Treatment. Lancet 2000.Google Scholar
  5. 5.
    Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. New Engl J Med 342: 301–307, 2000.PubMedCrossRefGoogle Scholar
  6. 6.
    Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279–1283, 1974.PubMedCrossRefGoogle Scholar
  7. 7.
    Williams AJK, Bingley PJ, Bonifacio E, Palmer JP, Gale EAM. A novel micro-assay for insulin autoantibodies. J Autoimmun 10: 473478, 1997.Google Scholar
  8. 8.
    Baekkeskov S, Aanstoot H-J, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H, DeCamilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABAsynthesizing enzyme glutamic acid decarboxylase [published erratum appears in Nature 1990 Oct 25;347(6295):782]. Nature 347: 151–156, 1990.PubMedCrossRefGoogle Scholar
  9. 9.
    Rabin DU, Pleasic SM, Shapiro JA, Yoo-Warren H, Oles J, Hicks JM, Goldstein DE, Rae PM. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J Immunol 152: 3183–3188, 1994.PubMedGoogle Scholar
  10. 10.
    Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA, Chase HP, Eisenbarth GS. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 45: 926–933, 1996.PubMedCrossRefGoogle Scholar
  11. 11.
    Bingley PJ, Bonifacio E, Williams AJ, Genovese S, Bottazzo GF, Gale, EA. Prediction of IDDM in the general population: strategies based on combinations of autoantibody markers. Diabetes 46: 1701 1710, 1997.Google Scholar
  12. 12.
    Bonifacio E, Bingley PJ, Shattock M, Dean BM, Dunger D, Gale EAM, Bottazzo GF. Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes. Lancet 335: 147–149, 1990.PubMedCrossRefGoogle Scholar
  13. 13.
    McCulloch DKPalmer JP. The appropriate use of B-cell function testing in the preclinical period of Type 1 diabetes. Diabetic Med 8: 800–804, 1991.CrossRefGoogle Scholar
  14. 14.
    Johnston C, Millward BA, Hoskins P, Leslie RD, Bottazzo GF, Pyke DA. Islet-cell antibodies as predictors of the later development of type 1 (insulin-dependent) diabetes. A study in identical twins. Diabetologia 32: 382–386, 1989.PubMedCrossRefGoogle Scholar
  15. 15.
    Yu J, Yu L, Bugawan TL, Erlich HA, Barriga K, Hoffman M, Rewers M, Eisenbarth GS. Transient anti-islet autoantibodies: infrequent occurrence and lack of association with genetic risk factors. J Clin Endocrinol Metab 85: 2421–2428, 2000.PubMedCrossRefGoogle Scholar
  16. 16.
    Yu J, Yu L, Bugawan TL, Erlich HA, Barriga K, Hoffman M, Rewers M, Eisenbarth GS. Transient anti-islet autoantibodies: infrequent occurrence and lack of association with genetic risk factors. J Clin Endocrinol Metab 85: 2421–2428, 2000.PubMedCrossRefGoogle Scholar
  17. 17.
    Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 42: 359–362, 1993.PubMedCrossRefGoogle Scholar
  18. 18.
    Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M, Lang DA. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 11: 299–303, 1994.PubMedCrossRefGoogle Scholar
  19. 19.
    Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2: 1279–1283, 1974.PubMedCrossRefGoogle Scholar
  20. 20.
    Levy-Marchal C, Papoz L, de Beaufort C, Doutreix J, Froment V, Voirin J, Czernichow P. Clinical and laboratory features of type I diabetic children at time of diagnosis. Diabetic Med 9: 279–284, 1992.PubMedCrossRefGoogle Scholar
  21. 21.
    Eberhardt MS, Wagener DK, Orchard TJ, LaPorte RE, Cavender DE, Rabin BS, Atchison RW, Kuller LH, Drash AL, Becker DJ. HLA heterogeneity of insulin-dependent diabetes mellitus at diagnosis. The Pittsburgh IDDM Study. Diabetes 34: 1247–1252, 1985.PubMedCrossRefGoogle Scholar
  22. 22.
    Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type I diabetes (insulin dependent) mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 29: 267–274, 1986.PubMedCrossRefGoogle Scholar
  23. 23.
    Childhood Diabetes Research Committee Ministry of Health and Welfare-Japan, Polish Diabetes Research Group–Poznan, The Netherlands Institute for Preventive Health Care — Leiden, Diabetes Research Center of Pittsburgh, Pennsylvania. How frequently do children die at the onset of insulin-dependent diabetes? Analyses of registry data from Japan, Poland, the Netherlands, and Allegheny County, Pennsylvania. Diab Nutr Metab 3: 57–62, 1990.Google Scholar
  24. 24.
    Kostraba JN, Gay EC, Rewers M, Chase HP, Klingensmith GJ, Hamman RF. Increasing trend of outpatient management of children with newly diagnosed IDDM. Colorado IDDM registry, 1978–88. Diabetes Care 15: 95–100, 1992.PubMedCrossRefGoogle Scholar
  25. 25.
    Pinkney JH, Bingley PJ, Sawtell PA, Dunger DB, Gale EAM, The Bart’s-Oxford Study Group. Presentation and progress of childhood diabetes mellitus: A prospective population-based study. Diabetologia 37: 70–74, 1994.CrossRefGoogle Scholar
  26. 26.
    Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23: 1516 1526, 2000.Google Scholar
  27. 27.
    Rewers M, Kostraba JN. Epidemiology of type I diabetes. In Type I diabetes: molecular, cellular, and clinical immunology. Eisenbarth GS, Lafferty KJ, eds., Oxford University Press, 9:172–208, 1996.Google Scholar
  28. 28.
    Pilcher CC, Dickens K, Elliott RB. ICA only develop in early childhood. Diabetes Res Clin Pract 14 (Suppl. 1): s82 - s82, 1991.Google Scholar
  29. 29.
    Rewers M, Stone RA, LaPorte RE, Drash AL, Becker DJ, Walczak M, Kuller LH. Poisson regression modeling of temporal variation in incidence of childhood insulin-dependent diabetes mellitus in Allegheny County, Pennsylvania, and Wielkopolska, Poland, 19701985. Am J Epidemiol 129: 569–581, 1989.PubMedGoogle Scholar
  30. 30.
    Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22: 345–354, 1999.PubMedCrossRefGoogle Scholar
  31. 31.
    Dabelea D, Hanson RL, Bennett PH, Roumain J, Knowler WC, Pettitt DJ. Increasing prevalence of Type II diabetes in American Indian children. Diabetologia 41: 904–910, 1998.PubMedCrossRefGoogle Scholar
  32. 32.
    Joner GSovik O. The incidence of type 1 (insulin-dependent) diabetes mellitus 15–29 years in Norway 1978–1982. Diabetologia 34: 271–274, 1991.CrossRefGoogle Scholar
  33. 33.
    Christau B, Kromann H, Andersen 00, Christy M, Buschard K, Arnung K, Kristensen IH, Peitersen B, Steinrud J, Nerup J. Incidence, seasonal and geographic patterns of juvenile-onset insulin-dependent diabetes mellitus is Denmark. Diabetologia 13 (4): 281–284, 1977.PubMedCrossRefGoogle Scholar
  34. 34.
    Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group [published erratum appears in Lancet 1998 Jan 31;351(9099):376]. Lancet 350: 1288–1293, 1997.PubMedCrossRefGoogle Scholar
  35. 35.
    Horton V, Stratton I, Bottazzo GF, Shattock M, Mackay I, Zimmet P, Manley S, Holman R, Turner R. Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group. Diabetologia 42: 608–616, 1999.PubMedCrossRefGoogle Scholar
  36. 36.
    Diabetes Epidemiology Research International Group. Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes 37: 1113–1119, 1988.CrossRefGoogle Scholar
  37. 37.
    Kostraba JN, Gay EC, Cai Y, Cruickshanks KJ, Rewers MJ, Klingensmith GJ, Chase HP, Hamman RF. Incidence of insulin-dependent diabetes mellitus in Colorado. Epidemiology 3: 232–238, 1992.PubMedCrossRefGoogle Scholar
  38. 38.
    Siemiatycki J, Colle E, Campbell S, Dewar RA, Belmonte MM. Case-control study of IDDM. Diabetes Care 12: 209–216, 1989.PubMedCrossRefGoogle Scholar
  39. 39.
    Zimmet PZ, Rowley MJ, Mackay IR, Knowles WJ, Chen QY, Chapman LH, Serjeantson SW. The ethnic distribution of antibodies to glutamic acid decarboxylase: presence and levels of insulin-dependent diabetes mellitus in Europid and Asian subjects. J Diabetes Complications 7: 1–7, 1993.PubMedCrossRefGoogle Scholar
  40. 40.
    Gale EAGillespie KM. Diabetes and gender. Diabetologia 44: 3–15, 2001.CrossRefGoogle Scholar
  41. 41.
    Diabetes Epidemiology Research International Group. Geographic patterns of childhood insulin-dependent diabetes mellitus. Diabetes 37: 1113–1119, 1988.CrossRefGoogle Scholar
  42. 42.
    Bruno G, Merletti F, Vuolo A, Pisu E, Giorio M, Pagano G. Sex differences in incidence of IDDM in age group 15–29 yr. Higher risk in males in Province of Turin, Italy. Diabetes Care 16 (1): 133–136, 1993.PubMedCrossRefGoogle Scholar
  43. 43.
    Gamble DR. The epidemiology of insulin-dependent diabetes, with particular reference to the relationship of virus infection to its etiology. Epidemiol Rev 2: 49–70, 1980.PubMedGoogle Scholar
  44. 44.
    Kostraba JN, Gay EC, Cai Y, Cruickshanks KJ, Rewers MJ, Klingensmith GJ, Chase HP, Hamman RF. Incidence of insulin-dependent diabetes mellitus in Colorado. Epidemiology 3: 232–238, 1992.PubMedCrossRefGoogle Scholar
  45. 45.
    Ludvigsson JAfoke AO. Seasonality of type 1 (insulin-dependent) diabetes mellitus: values of C-peptide, insulin antibodies and haemoglobin Al show evidence of a more rapid loss of insulin secretion in epidemic patients. Diabetologia 32: 84–91, 1989.CrossRefGoogle Scholar
  46. 46.
    Diabetes Epidemiology Research International Group. Secular trends in incidence of childhood IDDM in 10 countries. Diabetes 39: 858864, 1990.Google Scholar
  47. 47.
    Nystrom L, Dahlquist G, Rewers M, Wall S. The Swedish childhood diabetes study: an analysis of the temporal variation in diabetes incidence, 1978–1987. Int J Epidemiol 19: 141–146, 1990.PubMedCrossRefGoogle Scholar
  48. 48.
    Karvonen M, Pitkaniemi J, Tuomilehto J. The onset age of type 1 diabetes in Finnish children has become younger. The Finnish Childhood Diabetes Registry Group. Diabetes Care 22: 1066–1070, 1999.PubMedCrossRefGoogle Scholar
  49. 49.
    Cordell HJTodd JA. Multifactorial inheritance in type 1 diabetes. [Review]. Trends Genet 11: 499–504, 1995.CrossRefGoogle Scholar
  50. 50.
    Allen C, Palta M, D’Alessio DJ. Risk of diabetes in siblings and other relatives of IDDM subjects. Diabetes 40: 831–836, 1991.PubMedCrossRefGoogle Scholar
  51. 51.
    Lorenzen T, Pociot F, Hougaard P, Nerup J. Long-term risk of IDDM in first-degree relatives of patients with IDDM. Diabetologia 37: 32 1327, 1994.Google Scholar
  52. 52.
    O’Leary LA, Dorman JS, LaPorte RE, Orchard TJ, Becker DJ, Kuller LH, Eberhardt MS, Cavender DE, Rabin BS, Drash AL. Familial and sporadic insulin-dependent diabetes: Evidence for heterogeneous etiologies? Diab Res Clin Pract 14: 183–190, 1991.CrossRefGoogle Scholar
  53. 53.
    Erlich HA, Griffith RL, Bugawan TL, Ziegler R, Alper C, Eisenbarth G. Implication of specific DQB 1 alleles in genetic susceptibility and resistance by identification of IDDM siblings with novel HLA-DQB 1 allele and unusual DR2 and DR1 haplotypes. Diabetes 40: 478–481, 1991.PubMedCrossRefGoogle Scholar
  54. 54.
    Rewers M, Bugawan TL, Norris JM, Blair A, Beaty B, Hoffman M, McDuffie RS, Hamman RF, Klingensmith G, Eisenbarth GS, Erlich HA. Newborn screening for HLA markers associated with IDDM: Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia 39: 807–812, 1996.PubMedCrossRefGoogle Scholar
  55. 55.
    Greenbaum CJ, Cuthbertson D, Eisenbarth GS, Schatz DA, Zeidler A, Krischer JP. Islet cell antibody positive relatives with HLADQA1*0102, DQB1*0602: Identification by the Diabetes Prevention Trial-1. J Clin Endocrinol Metab 85: 1255–1260, 2000.PubMedCrossRefGoogle Scholar
  56. 56.
    Chase HP, Voss MA, Butler-Simon N, Hoops S, O’Brien D, Dobersen MJ. Diagnosis of pre-type I diabetes. J Pediatr 111: 807–812, 1987.PubMedCrossRefGoogle Scholar
  57. 57.
    Levy-Marchal C, Tichet J, Fajardy I, Dubois F, Czernichow P. Follow-up of children from a background population with high ICA titres. Diabetologia 35 Suppl 1: A32 - A32, 1992.Google Scholar
  58. 58.
    Cox NJ, Wapelhorst B, Morrison VA, Johnson L, Pinchuk L, Spielman RS, Todd JA, Concannon P. Seven regions of the genome show evidence of linkage to type 1 diabetes in a consensus analysis of 767 multiplex families. Am J Hum Genet 69: 820–830, 2001.PubMedCrossRefGoogle Scholar
  59. 59.
    Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, Reunanen A, Eriksson J, Stengard J, Kesaniemi YA. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 35: 1060–1067, 1992.PubMedCrossRefGoogle Scholar
  60. 60.
    Pak CY, Hyone-Myong E, McArthur RG, Yoon JW. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet 2: 1–3, 1988.PubMedCrossRefGoogle Scholar
  61. 61.
    Hyoty H, Hiltunen M, Reunanen A, Leinikki P, Vesikari T, Lounamaa R, Tuomilehto J, Akerblom HK. Decline of mumps antibodies in type 1 (insulin-dependent) diabetic children and a plateau in the rising incidence of type 1 diabetes after introduction of the mumps-measlesrubella vaccine in Finland. Childhood Diabetes in Finland Study Group. Diabetologia 36: 1303–1308, 1993.PubMedCrossRefGoogle Scholar
  62. 62.
    Ginsberg-Fellner F, Witt ME, Yagihashi S, Dobersen MJ, Taub F, Fedun B, Mcevoy RC, Roman SH, Davies RG, Cooper LZ, et al. Congenital rubella syndrome as a model for type 1 (insulin-dependent) diabetes mellitus: increased prevalence of islet cell surface antibodies. Diabetologia 27 Supp1: 87–89, 1984.Google Scholar
  63. 63.
    Conrad B, Weidmann E, Trucco G, Rudert WA, Behboo R, Ricordi C, Rodriquez-Rilo H, Finegold D, Trucco M. Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371: 351–355, 1994.PubMedCrossRefGoogle Scholar
  64. 64.
    Honeyman MC, Coulson BS, Stone NL, Gellert SA, Goldwater PN, Steele CE, Couper JJ, Tait BD, Colman PG, Harrison LC. Association between rotavirus infection and pancreatic islet autoimmunity in children at risk of developing type 1 diabetes. Diabetes 49: 1319–1324, 2000.PubMedCrossRefGoogle Scholar
  65. 65.
    Oldstone MB, Nerenberg M, Southern P, Price J, Lewicki H. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65: 319–331, 1991.PubMedCrossRefGoogle Scholar
  66. 66.
    Helmke K, Otten A, Willems WR, Brockhaus R, Mueller-Eckhardt G, Stief T, Bertrams J, Wolf H, Federlin K. Islet cell antibodies and the development of diabetes mellitus in relation to mumps infection and mumps vaccination. Diabetologia 29: 30–33, 1986.PubMedCrossRefGoogle Scholar
  67. 67.
    Bodansky HJ, Dean BM, Bottazzo GF, Grant PJ, McNally J, Hambling MH. Islet-cell antibodies and insulin autoantibodies in association with common viral infections. Lancet Dec 13: 1351–1353, 1986.CrossRefGoogle Scholar
  68. 68.
    Champsaur HF, Bottazzo GF, Bertrams J, Assan R, Bach C. Virologie, immunologic, and genetic factors in insulin-dependent diabetes mellitus. J Pediatr 100: 15–20, 1982.PubMedCrossRefGoogle Scholar
  69. 69.
    Blom L, Nystrom L, Dahlquist G. The Swedish childhood diabetes study. Vaccinations and infections as risk determinants for diabetes in childhood. Diabetologia 34: 176–181, 1991.PubMedCrossRefGoogle Scholar
  70. 70.
    Menser MA, Forrest JM, Bransby RD. Rubella infection and diabetes mellitus. Lancet 1: 57–60, 1978.PubMedCrossRefGoogle Scholar
  71. 71.
    Karounos DG, Wolinsky JS, Thomas JW. Monoclonal antibody to rubella virus capsid protein recognizes a n-cell antigen. J Immunol 150: 3080–3085, 1993.PubMedGoogle Scholar
  72. 72.
    Rewers M, Atkinson M. The possible role of enteroviruses in diabetes mellitus. 353–385, 1996.Google Scholar
  73. 73.
    Graves PM, Norris JM, Pallansch MA, Gerling IC, Rewers M. The role of enteroviral infections in the development of IDDM: limitations of current approaches. Diabetes 46: 161–168, 1997.PubMedCrossRefGoogle Scholar
  74. 74.
    Jenson AB, Rosenberg HS, Notkins AL. Pancreatic islet-cell damage in children with fatal viral infections. Lancet Aug 16: 354–358, 1980.Google Scholar
  75. 75.
    Wagenknecht LE, Roseman JM, Herman WH. Increased incidence of insulin-dependent diabetes mellitus following an epidemic of coxsackievirus B5. Am J Epidemiol 133: 1024–1031, 1991.PubMedGoogle Scholar
  76. 76.
    Kaufman DL, Clare-Salzler M, Tian J, Forsthuber T, Ting GS, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes [see comments]. Nature 366: 6972, 1993.CrossRefGoogle Scholar
  77. 77.
    Scherbaum WA, Hampl W, Muir P, Gluck M, Seibler J, Egle H, Hauner H, Boehm BO, Heinze E, Banatvala JE, Pfeiffer EF. No association between islet cell antibodies and coxsackie B, mumps, rubella and cytomegalovirus antibodies in non-diabetic individuals aged 7–19 years. Diabetologia 34: 835–838, 1991.PubMedCrossRefGoogle Scholar
  78. 78.
    Lonnrot M, Korpela K, Knip M, Ilonen J, Simell O, Korhonen S, Savola K, Muona P, Simell T, Koskela P, Hyoty H. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes 49: 1314–1318, 2000.PubMedCrossRefGoogle Scholar
  79. 79.
    Hyoty H, Hiltunen M, Knip M, Laakkonen M, Vahasalo P, Karjalainen J, Koskela P, Roivainen M, Leinikki P, Hovi T,. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 44: 652–657, 1995.PubMedCrossRefGoogle Scholar
  80. 80.
    Dahlquist G, Frisk G, Ivarsson SA, Svanberg L, Forsgren M, Diderholm H. Indications that maternal coxsackie B virus infection during pregnancy is a risk factor for childhood-onset IDDM. Diabetologia 38: 1371–1373, 1995.PubMedCrossRefGoogle Scholar
  81. 81.
    McKinney PA, Parslow R, Gurney KA, Law GR, Bodansky HJ, Williams R. Perinatal and neonatal determinants of childhood type 1 diabetes. A case-control study in Yorkshire, U.K. Diabetes Care 22: 928–932, 1999.CrossRefGoogle Scholar
  82. 82.
    Rothwell PM, Staines A, Smail P, Wadsworth E, McKinney P. Seasonality of birth of patients with childhood diabetes in Britain. BMJ 312: 1456–1457, 1996.PubMedCrossRefGoogle Scholar
  83. 83.
    Wilberz S, Partke HJ, Dagnaes-Hansen F, Herberg L. Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in non-obese diabetic mice. Diabetologia 34: 2–5, 1991.PubMedCrossRefGoogle Scholar
  84. 84.
    McKinney PA, Okasha M, Parslow RC, Law GR, Gurney KA, Williams R, Bodansky HJ. Early social mixing and childhood Type 1 diabetes mellitus: a case-control study in Yorkshire, UK. Diabet Med 17: 236–242, 2000.PubMedCrossRefGoogle Scholar
  85. 85.
    Infections and vaccinations as risk factors for childhood type I (insulin-dependent) diabetes mellitus: a multicentre case-control investigation. EURODIAB Substudy 2 Study Group. Diabetologia 43:47–53, 2000.Google Scholar
  86. 86.
    Graves PM, Barriga KJ, Norris JM, Hoffman MR, Yu L, Eisenbarth GS, Rewers M. Lack of association between early childhood immunizations and beta-cell autoimmunity. Diabetes Care 22: 1694 1697, 1999.Google Scholar
  87. 87.
    Atkinson MA, Winter WE, Skordis N, Beppu H, Riley WM, Maclaren NK. Dietary protein restriction reduces the frequency and delays the onset of insulin dependent diabetes in BB rats. Autoimmunity 2: 1120, 1988.CrossRefGoogle Scholar
  88. 88.
    Martin JM, Trink B, Daneman D, Dosch H-M, Robinson B. Milk proteins in the etiology of insulin-dependent diabetes mellitus (IDDM). Ann Med 23: 447–452, 1991.PubMedCrossRefGoogle Scholar
  89. 89.
    Couper JJ, Steele C, Beresford S, Powell T, McCaul K, Pollard A, Gellert S, Tait B, Harrison LC, Colman PG. Lack of association between duration of breast-feeding or introduction of cow’s milk and development of islet autoimmunity. Diabetes 48: 2145–2149, 1999.PubMedCrossRefGoogle Scholar
  90. 90.
    Borch-Johnsen K, Joner G, Mandrup-Poulsen T, Christy M, ZachauChristiansen B, Kastrup K, Nerup J. Relation between breast-feeding and incidence rates of insulin-dependent diabetes mellitus. Lancet 2: 1083–1086, 1984.PubMedCrossRefGoogle Scholar
  91. 91.
    Mayer EJ, Hamman RF, Gay EC, Lezotle DC, Savitz DA, Klingensmith GJ. Reduced risk of IDDM among breast-fed children. The Colorado IDDM Registry. Diabetes 37: 1625–1632, 1988.PubMedCrossRefGoogle Scholar
  92. 92.
    Nigro G, Campea L, De Novellis A, Orsini M. Breast-feeding and insulin-dependent diabetes mellitus. Lancet 1:467 (Letter)-1985.Google Scholar
  93. 93.
    Kyvik KO, Green A, Svendsen A, Mortensen K. Breast feeding and the development of type I diabetes mellitus. Diabetic Med 9: 233–235, 1992.PubMedCrossRefGoogle Scholar
  94. 94.
    Virtanen SM, Rasanen L, Aro A, Ylonen K, Lounamaa R, Tuomilehto J, Akerblom HK, the ‘Childhood Diabetes in Finland’ Study Group. Feeding in infancy and the risk of type 1 diabetes mellitus in Finnish children. Diabetic Med 9: 815–819, 1992.PubMedCrossRefGoogle Scholar
  95. 95.
    Gerstein HC. Cow’s milk exposure and type I diabetes mellitus–a critical overview of the clinical literature. Diabetes Care 17: 13–19, 1994.PubMedCrossRefGoogle Scholar
  96. 96.
    Norris JMScott FW. A meta-analysis of infant diet and insulin-dependent diabetes mellitus: do biases play a role? Epidemiology 7: 87–92, 1996.CrossRefGoogle Scholar
  97. 97.
    Savilahti E, Akerblom HK, Tainio VM, Koskimies S. Children with newly diagnosed insulin dependent diabetes mellitus have incresed levels of cow’s milk antibodies. Diabetes Res 7: 137–140, 1988.PubMedGoogle Scholar
  98. 98.
    Karjalainen J, Martin JM, Knip M, Ilonen J, Robinson BH, Savilahti E, Akerblom HK, Dosch HM. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus [see comments]. N Engl J Med 327: 302–307, 1992.PubMedCrossRefGoogle Scholar
  99. 99.
    Hummel M, Fuchtenbusch M, Schenker M, Ziegler AG. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 23: 969–974, 2000.PubMedCrossRefGoogle Scholar
  100. 100.
    Virtanen SM, Laara E, Hypponen E, Reijonen H, Rasanen L, Aro A, Knip M, Ilonen J, Akerblom HK. Cow’s milk consumption, HLADQB1 genotype, and type 1 diabetes: a nested case-control study of siblings of children with diabetes. Childhood diabetes in Finland study group [In Process Citation]. Diabetes 49: 912–917, 2000.PubMedCrossRefGoogle Scholar
  101. 101.
    Paronen J, Knip M, Savilahti E, Virtanen SM, Ilonen J, Akerblom HK, Vaarala O. Effect of cow’s milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Finnish Trial to Reduce IDDM in the Genetically at Risk Study Group. Diabetes 49: 1657–1665, 2000.PubMedCrossRefGoogle Scholar
  102. 102.
    Elias D, Prigozin H, Polak N, Rapoport M, Lohse AW, Cohen IR. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Diabetes 43: 992–998, 1994.PubMedCrossRefGoogle Scholar
  103. 103.
    Rayfield EJlshimura K. Environmetal factors and insulin dependent diabetes mellitus. Diabetes Metab Rev 3: 925–957, 1987.CrossRefGoogle Scholar
  104. 104.
    Dahlquist GG, Blom LG, Persson L-A, Sandström AIM, Wall SGI. Dietary factors and the risk of developing insulin dependent diabetes in childhood. Br Med J 300: 1302–1306, 1990.CrossRefGoogle Scholar
  105. 105.
    Toniolo A, Onodera T, Yoon JW, Notkins AL. Induction of diabetes by cumulative environmental insults from viruses and chemicals. Nature 288: 383–385, 1980.PubMedCrossRefGoogle Scholar
  106. 106.
    Khoury MJ, Flanders WD, Greenland S, Adams MJ. On the measurement of susceptibility in epidemiologic studies. Am J Epidemiol 129: 183–190, 1989.PubMedGoogle Scholar
  107. 107.
    Fohlman J, Bohme J, Rask L, Frisk G, Diderholm H, Friman G, Tuvemo T. Matching of host genotype and serotypes of Coxsackie B virus in the development of juvenile diabetes. Scand J Immunol 26: 105–110, 1987.PubMedCrossRefGoogle Scholar
  108. 108.
    Kostraba JN, Cruickshanks KJ, Lawler-Heavner J, Jobim LF, Rewers MJ, Gay EC, Chase HP, Klingensmith G, Hamman RF. Early exposure to cow’s milk and solid foods in infancy, genetic predisposition and risk of IDDM. Diabetes 42: 288–295, 1993.PubMedCrossRefGoogle Scholar
  109. 109.
    Norris JM, Beaty B, Klingensmith G, Yu L, Hoffman M, Chase HP, Erlich HA, Hamman RF, Eisenbarth GS, Rewers M. Lack of association between early exposure to cow’s milk protein and [3-cell autoimmunity: Diabetes Autoimmunity Study in the Young (DAISY). JAMA 276: 609–614, 1996.CrossRefGoogle Scholar
  110. 110.
    Ortqvist E, Falorni A, Scheynius A, Persson B, Lernmark A. Age governs gender-dependent islet cell autoreactivity and predicts the clinical course in childhood IDDM. Acta Paediatr 86: 1166–1171, 1997.PubMedCrossRefGoogle Scholar
  111. 111.
    Wallensteen M, Dahlquist G, Persson B, Landin-Olsson M, Lernmark A, Sundkvist G, Thalme B. Factors influencing the magnitude, duration, and rate of fall of B-cell function in Type I (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 31: 664–669, 1988.PubMedCrossRefGoogle Scholar
  112. 112.
    Agner T, Damm P, Binder C. Remission in IDDM: prospective study of basal C-peptide and insulin dose in 268 consecutive patients. Diabetes Care 10: 164–169, 1987.PubMedCrossRefGoogle Scholar
  113. 113.
    Fukuda M, Tanaka A, Tahara Y, Ikegami H, Yamamoto Y, Kumahara Y, Shima K. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 37: 8188, 1988.CrossRefGoogle Scholar
  114. 114.
    Schiffrin A, Suissa S, Poussier P, Guttmann R, Weitzner G. Prospective study of predictors of beta-cell survival in type I diabetes. Diabetes 37: 920–925, 1988.PubMedCrossRefGoogle Scholar
  115. 115.
    Kolb H, Dannehl K, Gruenklee D, Zielasek J, Bertrams J, Hubinger A, Gries FA. Prospective analysis of islet cell antibodies in children with type I (insulin-dependent) diabetes. Diabetologia 31: 189–194, 1988.PubMedCrossRefGoogle Scholar
  116. 116.
    Knip M, Llonen J, Mustonen A, Akerblom HK. Evidence of an accelerated B-cell destruction in HLA-Dw3/Dw4 heterozygous children with type I (insulin-dependent) diabetes. Diabetologia 29: 347–351, 1986.PubMedCrossRefGoogle Scholar
  117. 117.
    Pipeleers DLing Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 8: 209–227, 1992.CrossRefGoogle Scholar
  118. 118.
    Madsbad S, Faber OK, Binder C, McNair P, Christiansen C, Transbol I. Prevalence of residual beta-cell function in insulin-dependent diabetics in relation to age at onset and duration of diabetes. Diabetes 27 (Suppl. 1): 262–264, 1978.PubMedGoogle Scholar
  119. 119.
    WHO Study Group. Diabetes Mellitus - Technical Report Series 727. 1985.Google Scholar
  120. 120.
    Songer TJ. Health services and costing in diabetes. Med J Aust 152: 115–117, 1990.PubMedGoogle Scholar
  121. 121.
    Dorman JS, LaPorte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 33: 271–276, 1984.PubMedCrossRefGoogle Scholar
  122. 122.
    Major cross-country differences in risk of dying for people with IDDM. Diabetes Epidemiology Research International Mortality Study Group. Diabetes Care 14: 49–54, 1991.CrossRefGoogle Scholar
  123. 123.
    Matsushima M, LaPorte RE, Maruyama M, Shimizu K, Nishimura R, Tajima N, for the DERI Mortality Study Group. Geographic variation in mortality among individuals with youth-onset diabetes mellitus across the world. Diabetologia 40: 212–216, 1997.PubMedCrossRefGoogle Scholar
  124. 124.
    International evaluation of cause-specific mortality and IDDM. Diabetes Epidemiology Research International Mortality Study Group. Diabetes Care 14: 55–60, 1991.CrossRefGoogle Scholar
  125. 125.
    Borch-Johnsen K, Nissen H, Henriksen E, Kreiner S, Salling N, Deckert T, Nerup J. The natural history of insulin-dependent diabetes mellitus in Denmark: 1. Long-term survival with and without late diabetic complications. Diabetic Med 4: 201–210, 1987.PubMedCrossRefGoogle Scholar
  126. 126.
    Chowdhury TA, Dyer PH, Mijovic CH, Dunger DB, Barnett AH, Bain SC. Human leucocyte antigen and insulin gene regions and nephropathy in Type I diabetes. Diabetologia 42: 1017–1020, 1999.PubMedCrossRefGoogle Scholar
  127. 127.
    Doria A, Onuma T, Gearin G, Freire MB, Warram JH, Krolewski AS. Angiotensinogen polymorphism M235T, hypertension, and nephropathy in insulin-dependent diabetes. Hypertension 27: 1134 1139, 1996.Google Scholar
  128. 128.
    Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz, J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99: 62–66, 1997.PubMedCrossRefGoogle Scholar
  129. 129.
    Rewers M, Kamboh MI, Hoag S, Shetterly SM, Ferrell RE, Hamman RF. Apolipoprotein A-IV polymorphism associated with myocardial infarction in obese NIDDM patients. The San Luis Valley Diabetes Study. Diabetes 43: 1485–1489, 1994.PubMedCrossRefGoogle Scholar
  130. 130.
    Notkins ALYoon JW. Virus-induced diabetes in mice prevented by a live attenuated vaccine. N Engl J Med 306: 486–1982.Google Scholar
  131. 131.
    See DMTilles JG. WIN 54954 treatment of mice infected with a diabetogenic strain of group B coxsackievirus. Antimicrob Agents Chemother 37: 1593–1598, 1993.CrossRefGoogle Scholar
  132. 132.
    Eisenbarth GS, Verge CF, Allen H, Rewers MJ. The design of trials for prevention of IDDM. Diabetes 42: 941–947, 1993.PubMedCrossRefGoogle Scholar
  133. 133.
    Gale EA. Theory and practice of nicotinamide trials in pre-type 1 diabetes. J Pediatr Endocrinol Metab 9: 375–379, 1996.PubMedCrossRefGoogle Scholar
  134. 134.
    Knip M, Douek IF, Moore WP, Gillmor HA, McLean AE, Bingley PJ, Gale EA. Safety of high-dose nicotinamide: a review. Diabetologia 43: 1337–1345, 2000.PubMedCrossRefGoogle Scholar
  135. 135.
    Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H. The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes. DENIS Group. Diabetes 47: 980984, 1998.Google Scholar
  136. 136.
    Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type I diabetes. Lancet 341:927–928, 1993. 177Google Scholar
  137. 137.
    Pozzilli P, Pitocco D, Visalli N, Cavallo MG, Buzzetti R, Crino A, Spera S, Suraci C, Multari G, Cervoni M, Manca BM, Matteoli MC, Marietti G, Ferrazzoli F, Cassone FM, Giordano C, Sbriglia M, Sarugeri E, Ghirlanda G. No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group [In Process Citation]. Diabetologia 43: 1000–1004, 2000.PubMedCrossRefGoogle Scholar
  138. 138.
    Lipton R, LaPorte RE, Becker DJ, Dorman JS, Orchard TJ, Atchison J, Drash AL. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care 13: 776–784, 1990.PubMedCrossRefGoogle Scholar
  139. 139.
    Feutren G, Assan G, Karsenty G, DuRostu H, Sirmai J, Papoz L, Vialettes B, Vexiau P, Rodier M, Lallemand A, Bach JF. Cyclosporin increases the rate and length of remissions in insulin dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 2: 119–124, 1986.PubMedCrossRefGoogle Scholar
  140. 140.
    Martin S, Schernthaner G, Nerup J, Gries FA, Koivisto VA, Dupre J, Standl E, Hamet P, McArthur R, Tan MH, et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 34: 429–434, 1991.PubMedCrossRefGoogle Scholar
  141. 141.
    Shah SC, Malone JI, Simpson NE. A randomized trial of intensive insulin therapy in newly diagnosed insulin-dependent diabetes mellitus. N Engl J Med 320: 550–554, 1989.PubMedCrossRefGoogle Scholar
  142. 142.
    Allen HF, Klingensmith GJ, Jensen P, Simoes E, Hayward A, Chase HP. Effect of BCG vaccination on new-onset insulin-dependent diabetes mellitus: A randomized clinical study. Diabetes Care 22: 1703–1707, 1998.CrossRefGoogle Scholar
  143. 143.
    Herold KC, Bluestone JA, Montag AG, Parihar A, Wiegner A, Gress RE, Hirsch R. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 41: 385–391, 1992.PubMedCrossRefGoogle Scholar
  144. 144.
    Hao L, Chan S-M, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci 328–332, 1993.Google Scholar
  145. 145.
    Vincenti F, Kirkman R, Light S, Blumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J, Daclizumab Triple Therapy Study Group. Interleukin-2receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338: 161–165, 1998.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Marian Rewers

There are no affiliations available

Personalised recommendations